JP2019505541A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505541A5
JP2019505541A5 JP2018543101A JP2018543101A JP2019505541A5 JP 2019505541 A5 JP2019505541 A5 JP 2019505541A5 JP 2018543101 A JP2018543101 A JP 2018543101A JP 2018543101 A JP2018543101 A JP 2018543101A JP 2019505541 A5 JP2019505541 A5 JP 2019505541A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
pharmaceutically acceptable
solvate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543101A
Other languages
English (en)
Japanese (ja)
Other versions
JP6912486B2 (ja
JP2019505541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000237 external-priority patent/WO2017141116A1/en
Publication of JP2019505541A publication Critical patent/JP2019505541A/ja
Publication of JP2019505541A5 publication Critical patent/JP2019505541A5/ja
Priority to JP2021112227A priority Critical patent/JP7289876B2/ja
Application granted granted Critical
Publication of JP6912486B2 publication Critical patent/JP6912486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543101A 2016-02-19 2017-02-17 Rsk阻害剤として有用なカルボキサミド誘導体 Active JP6912486B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021112227A JP7289876B2 (ja) 2016-02-19 2021-07-06 Rsk阻害剤として有用なカルボキサミド誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297522P 2016-02-19 2016-02-19
US62/297,522 2016-02-19
PCT/IB2017/000237 WO2017141116A1 (en) 2016-02-19 2017-02-17 Carboxamide derivatives useful as rsk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021112227A Division JP7289876B2 (ja) 2016-02-19 2021-07-06 Rsk阻害剤として有用なカルボキサミド誘導体

Publications (3)

Publication Number Publication Date
JP2019505541A JP2019505541A (ja) 2019-02-28
JP2019505541A5 true JP2019505541A5 (enExample) 2020-03-26
JP6912486B2 JP6912486B2 (ja) 2021-08-04

Family

ID=59625645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543101A Active JP6912486B2 (ja) 2016-02-19 2017-02-17 Rsk阻害剤として有用なカルボキサミド誘導体
JP2021112227A Active JP7289876B2 (ja) 2016-02-19 2021-07-06 Rsk阻害剤として有用なカルボキサミド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021112227A Active JP7289876B2 (ja) 2016-02-19 2021-07-06 Rsk阻害剤として有用なカルボキサミド誘導体

Country Status (14)

Country Link
US (4) US10758530B2 (enExample)
EP (2) EP3416964B1 (enExample)
JP (2) JP6912486B2 (enExample)
KR (1) KR102746242B1 (enExample)
CN (2) CN109071542B (enExample)
AU (1) AU2017220738B2 (enExample)
CO (1) CO2018008846A2 (enExample)
DK (1) DK3416964T3 (enExample)
ES (1) ES2858753T3 (enExample)
IL (1) IL261170B (enExample)
MX (1) MX376974B (enExample)
PL (1) PL3416964T3 (enExample)
PT (1) PT3416964T (enExample)
WO (1) WO2017141116A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2016154019A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
IL280619B2 (en) 2015-07-07 2023-10-01 H Lundbeck As Phosphodiesterase 9 inhibitors with an imidazo triazinon or imidazo pyrazinone skeleton for the treatment of peripheral diseases
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
PL3416964T3 (pl) 2016-02-19 2021-10-18 Phoenix Molecular Designs Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
AU2018300272B2 (en) 2017-07-14 2024-09-19 Orbsen Therapeutics Limited CD39 stromal stem cells methods of isolation and use
EP4349403A3 (en) 2018-05-25 2024-06-05 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
CN109847063B (zh) * 2018-12-26 2023-02-28 南方医科大学皮肤病医院(广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心) Rsk信号通路抑制剂在抑制沙眼衣原体感染中的应用
CN109438403A (zh) * 2018-12-28 2019-03-08 凯瑞斯德生化(苏州)有限公司 一种5-氨基苯并呋喃-2-甲酸乙酯的制备方法
CN113677681A (zh) * 2019-02-11 2021-11-19 凤凰分子设计公司 Rsk抑制剂的结晶形式
TW202307005A (zh) * 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法
PT4426434T (pt) 2021-11-02 2025-11-24 Flare Therapeutics Inc Agonistas inversos de pparg e suas utilizações
CN119451961A (zh) * 2022-06-07 2025-02-14 广州科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5792763A (en) 1996-10-08 1998-08-11 Eli Lilly And Company Serotonin 5-HT1F agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US6416780B1 (en) 1997-05-07 2002-07-09 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
AU2003224257A1 (en) * 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
US8765802B2 (en) * 2007-06-12 2014-07-01 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
JP5416122B2 (ja) * 2007-09-14 2014-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン F1F0−ATPaseインヒビターおよび関連の方法
GB0718870D0 (en) 2007-09-27 2007-11-07 Univ Dundee Modulation of RSK
US9073926B2 (en) 2009-12-07 2015-07-07 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
WO2013181742A1 (en) 2012-06-04 2013-12-12 Phoenix Molecular Diagnostics Ltd. Methods of inhibiting rsk for treatment of breast cancer
CA2897200C (en) * 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
CN103724251B (zh) * 2014-01-18 2015-07-22 福州大学 一种靶向stat3的小分子化合物及其制备方法和应用
CN106132963B (zh) 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪
PL3416964T3 (pl) 2016-02-19 2021-10-18 Phoenix Molecular Designs Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego

Similar Documents

Publication Publication Date Title
JP2019505541A5 (enExample)
JP2014503574A5 (enExample)
JP2014526549A5 (enExample)
JP2014525427A5 (enExample)
JP2017504635A5 (enExample)
JP2010518026A5 (enExample)
JP2014521653A5 (enExample)
JP2014139226A5 (enExample)
JP2016516043A5 (enExample)
SI3018132T1 (en) Condensed imidazole derivatives useful as IDO inhibitors
JP2017511794A5 (enExample)
JP2009526072A5 (enExample)
JP2016529324A5 (enExample)
JP2015520769A5 (enExample)
JP2017502940A5 (enExample)
JP2015537020A5 (enExample)
JP2020502092A5 (enExample)
JP2014525426A5 (enExample)
JP2015529224A5 (enExample)
JP2017530199A5 (enExample)
JP2011509309A5 (enExample)
JP2017533968A5 (enExample)
JP2015503609A5 (enExample)
JP2015524472A5 (enExample)
JP2017532360A5 (enExample)